Satisfaction with Control of Mild to Moderate Atopic Dermatitis with Ruxolitinib Cream: US Physician and Patient Perspectives

• Главные авторы: Lawrence F. Eichenfield (Автор), Jinan Liu (Автор), Simran Marwaha (Автор), James Piercy (Автор), Daniel Sturm (Автор), Peter Anderson (Автор)
• Формат: ‌
• Опубликовано: Adis, Springer Healthcare, 2024-03-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Abstract Introduction The 2021 US approval of ruxolitinib cream for treatment of atopic dermatitis (AD) in patients aged ≥ 12 years was based on the results of two pivotal phase 3 studies. Currently, real-world data to describe effectiveness of ruxolitinib cream and physician satisfaction with treat...